Annovis Bio (ANVS) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rallybio (RLYB) has outperformed Annovis Bio (ANVS) over the past year, gaining 208.4% versus a loss of 81.2%. Over five years, RLYB leads with a -85.3% price change compared with -97.2% for ANVS. Annovis Bio is the larger company by market cap ($44.1 million vs $43.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | RLYB |
|---|---|---|
| Share price | $0.7113 | $15.47 |
| Market cap | $44.12M | $43.32M |
| 1-day change | -4.96% | -0.32% |
| YTD return | -79.44% | +181.89% |
| 1-year return | -81.23% | +208.41% |
| 5-year return | -97.24% | -85.29% |
| P/E ratio (TTM) | — | 3.36 |
| EPS (TTM) | $-1.55 | $4.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $858.00K |
| Revenue growth (YoY) | — | +34.91% |
| Net income (latest FY) | $-28.85M | $-8.98M |
| Operating margin | — | -3853.61% |
| Net margin | — | -1046.39% |
| 52-week high | $5.50 | $35.15 |
| 52-week low | $0.62 | $7.34 |
| Distance from 52-week high | -87.07% | -55.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +1376.17% | — |
| Average volume | 1.82M | 10.14K |
| Shares outstanding | 62.02M | 2.80M |
| Employees | 7 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed ANVS by 289.6 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ANVS vs RLYB FAQ
Which is bigger, Annovis Bio or Rallybio?
Annovis Bio (ANVS) is larger, with a market capitalization of $44.12M compared with $43.32M for Rallybio (RLYB).
Which stock has performed better over the past year, ANVS or RLYB?
RLYB returned +208.41% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.